Login to Your Account

MolMed Adding $6.5M Ahead of Key Program Milestones

By Cormac Sheridan
Staff Writer

Wednesday, January 23, 2013
With key regulatory and clinical events fast approaching, MolMed SpA is set to add about €5 million (US$6.5 million) to its balance sheet in a capital increase that is fully underwritten in all but name.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription